Relationship between the concentration of ergothioneine in plasma and the likelihood of developing pre-eclampsia

Competing Interest Statement

DBK is a named inventor on a patent (WO2020221795) describing the production of ergothioneine in yeast. Leslie W. Brown, Paloma Ortea and Robin Tuytten are employees of Metabolomic Diagnostics, and they and Louise C. Kenny are minority shareholders of Metabolomic Diagnostics. Leslie W. Brown, Robin Tuytten, and Louise C. Kenny are named inventors on a Patent Application which discloses the use of specific proteins and metabolites to predict pre-eclampsia risk, and which is assigned to Metabolomic Diagnostics, i.e., Methods of predicting pre term birth from pre-eclampsia using metabolic and protein biomarkers, with publication number WO2019155075A1.

Funding Statement

This study received funding from the EU-HEALTH Project IMPROvED (305169) of the Seventh Framework Programme, the goal of IMPROvED is to develop a clinically robust predictive blood test for pre-eclampsia. SCOPE was funded by the New Enterprise Research Fund, Foundation for Research Science and Technology; Health Research Council; and Evelyn Bond Fund, Auckland District Health Board Charitable Trust (New Zealand); Premiers Science and Research Fund, South Australian Government (Australia); and Health Research Board (Ireland). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. DBK is supported by the Novo Nordisk Foundation (grant NNF20CC0035580).

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Ethics approval was gained from local ethics committees of each participating centre (Manchester, Leeds, and London 06/MRE01/98, Cork ECM5 (10) 05/02/08). Collection of data and biological samples complied with standardised procedures in all participating centres and was conducted in accordance with the principles of the Declaration of Helsinki.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes